Alane P. Barnes - May 11, 2021 Form 4 Insider Report for BIOCRYST PHARMACEUTICALS INC (BCRX)

Role
Chief Legal Officer
Signature
/s/ Alane P. Barnes
Stock symbol
BCRX
Transactions as of
May 11, 2021
Transactions value $
-$642,449
Form type
4
Date filed
5/13/2021, 04:43 PM
Next filing
Jan 13, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BCRX Common Stock Options Exercise $7.8K +1.65K +1.49% $4.73 112K May 11, 2021 Direct
transaction BCRX Common Stock Options Exercise $47K +33.1K +29.6% $1.42* 145K May 11, 2021 Direct
transaction BCRX Common Stock Options Exercise $371K +68K +46.88% $5.45 213K May 11, 2021 Direct
transaction BCRX Common Stock Sale -$1.24M -103K -48.24% $12.04 110K May 11, 2021 Direct F1
transaction BCRX Common Stock Options Exercise $170K +35.9K +32.51% $4.73 146K May 12, 2021 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BCRX Emp. Stock Option (Right to Buy) Options Exercise $0 -1.65K -4.39% $0.00 35.9K May 11, 2021 Common Stock 1.65K $4.73 Direct
transaction BCRX Emp. Stock Option (Right to Buy) Options Exercise $0 -33.1K -100% $0.00* 0 May 11, 2021 Common Stock 33.1K $1.42 Direct
transaction BCRX Emp. Stock Option (Right to Buy) Options Exercise $0 -68K -100% $0.00* 0 May 11, 2021 Common Stock 68K $5.45 Direct F3
transaction BCRX Emp. Stock Option (Right to Buy) Options Exercise $0 -35.9K -100% $0.00* 0 May 12, 2021 Common Stock 35.9K $4.73 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $12.00 to $12.15. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F2 The reporting person engaged in a non-market exercise and hold transaction with respect to these stock options and the underlying shares.
F3 The option vested upon the achievement of performance-based vesting criteria with respect to 17,000 shares on each of May 26, 2014, December 19, 2014, May 13, 2015 and December 3, 2020.